|
|
|
23.05.25 - 07:00
|
Outcome of Innate Pharma′s 2025 Annual General Meeting (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#AG--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 22, 2025, in Marseille. All resolutions were voted.
A total of 114 votes were cast out of a total of 43,447,237 shares giving right to 43,535,215 voting rights, representing a quorum of 47,14%.
Following the approval of its shareholders at the Annual General Meeting held on May 22, 2025, the Company has transitioned from an Executive Board and Supervisory Board corporate governance structure to a Board of Directors structure with a Chief Executive Officer.
New Governance Structure
The newly appointed Board of Directors comprises:
-
Mrs. Irina Staatz-Granzer;
-
Mr. Jonathan Dickinson;
-
Mrs. Véronique Chabernaud;
-
Mrs. Pascale Boissel;
-
Mrs. Sally Bennett;
-
Mr. Christian Itin;
-
Mr. Marty J. Duvall; and
-
Bpifrance Participations, represented b...
|
|
|
19.05.25 - 07:06
|
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting (Business Wire)
|
|
|
Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides
Trial in Progress poster on IPH4502, Innate's differentiated ADC in development in advanced solid tumors expressing Nectin-4
AstraZeneca to present a poster on updated results from the Phase 2 trial NeoCOAST-2 in resectable NSCLC
MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.
“We are looking forward to participating in the ASCO Annual Meeting 2025, where four abstracts with Innate's drugs in clinical development have been selected. In particular, we are pleased to share the long-term follow-up data from the TELLOMAK Phase 2 study, which underscores our continued commitment to advan...
|
|
|
|
|
|
|
13.05.25 - 07:03
|
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results (Business Wire)
|
|
|
€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET® program in autoimmune indications
First patient dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumors. Presentations at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting
FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome; long term follow up data from TELLOMAK Phase 2 to be presented at ASCO Annual Meeting 2025
Cash position of €72.5 million1 as of March 31, 2025, excluding the €15 million received from Sanofi, with a cash horizon to mid 2026
Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. ET
MARSEILLE, France--(BUSINESS WIRE)--#ADC--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2025.
“The first quarter of 2025 was marked...
|
|
|
06.05.25 - 07:06
|
Innate Pharma announces conference call and webcast for Q1 2025 business update (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#innatepharma--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 13, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2025.
In addition, members of the executive management team will be meeting with investors in New York and Boston from May 13 to May 14, 2025.
Participants during the call will be:
Jonathan Dickinson, Chief Executive Officer
Sonia Quaratino, Executive Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Details for the Virtual Event
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/806006771
Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4I2274040...
|
|
|
30.04.25 - 17:33
|
Innate Pharma Files Its 2024 Universal Registration Document (Document d′enregistrement universel) and 2024 Annual Report on Form 20-F (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2024 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 30, 2025. It can be downloaded (in French) on the Company's website and on the AMF's website.
The Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2024 with the United States Securities and Exchange Commission (“SEC”). It can be also be accessed on the Company's website and on the SEC's website.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell En...
|
|
|
24.04.25 - 07:36
|
Innate Pharma Announces €15M Investment by Sanofi (Business Wire)
|
|
|
Investment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeting ANKET® program in autoimmune indications, and more
MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscribed by Sanofi.
As announced on April 23, 2025, and given the satisfactory market conditions, Sanofi has agreed to subscribe to 8,345,387 new ordinary shares of Innate, at a price of €1.7974 per share, representing a total capital increase of €14,999,998.59 (€417,269.35 in nominal amount and €14,582,729.24 of issue premium).
The subscription price of €1.7974 per share (€0.05 in nominal amount and €1.7474 of issue premium) is equal to the daily volume-weighted average price of the ordinary shares of Innate on the regulated market of Euronext in Paris on April 23, 2025.
“We welcome Sanofi's strategic investm...
|
|
|
23.04.25 - 07:06
|
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi′s Intention to Make a Strategic Investment in the Company (Business Wire)
|
|
|
Innate to regain its rights on CD123 targeting ANKET® SAR443579 (SAR'579) /IPH6101 currently in development for AML
Potential investment of up to €15M by Sanofi in Innate Pharma through a capital increase, subject to market conditions
Sanofi to continue development of BCMA targeting ANKET® program in autoimmune indications
Innate still eligible for more than €1 billion R&D and commercial milestones
MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Research Collaboration and License Agreement (the “2016 Agreement”) with Sanofi:
As previously disclosed and in alignment with its current strategic priorities, Sanofi will opt to pursue the development of SAR'514/IPH6401 (BCMA ANKET®) in autoimmune indications under the terms of the 2016 License Agreement;
In alignment with both company's current strategic priorities, Sanofi and Innate agreed to terminate ...
|
|
|
16.04.25 - 07:03
|
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025 (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its annual general meeting of shareholders (“AGM”) at 10:30 a.m. CEST on May 22, 2025 in its headquarters, 117 avenue de Luminy, 13009 Marseille.
The Notice of Meeting of this AGM was published on April 16, 2025 in the French legal bulletin. It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this AGM.
Documents and information relating to this meeting will be made available to shareholders in accordance with current regulations, and will also be available in the Investors section of the Company's website.
****
The annual general meeting will also be broadcasted live and available at the following link:
Innate Pharma 2025 annual general meeting
A guided tour of the Company's laboratories is organized on the same day at 9:15 a.m. CEST for shareholders. Shareholders can register for the tour at this lin...
|
|
|
16.04.25 - 07:03
|
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition (Business Wire)
|
|
|
Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors
Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of the board of Directors
Jonathan Dickinson, current Chairman of the Executive board would be appointed Chief Executive Officer and named to the board of Directors
Two new members would join the board of Directors
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to one with a CEO/board of directors. This transformation is part of the Company's strategic plan to simplify and align its governance with international standards.
It will be proposed that shareholders app...
|
|
|
|
|
27.03.25 - 07:06
|
Innate Pharma Reports Full Year 2024 Financial Results and Business Update (Business Wire)
|
|
|
FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome
New data, including lacutamab improved health-related quality of life data from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma were presented at ASH 2024
The first patient was dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumors
IPH6501, Innate's proprietary ANKET® drug candidate, is being evaluated in a Phase 1/2 clinical trial in patients with B-cell non-Hodgkin's lymphoma
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announced up to $7.9m investment from IFLI to support IPH6501 development in Follicular Lymphoma
Cash position of €91.1 million1 as of December 31, 2024 with a cash horizon extended to mid 2026
Conference call to be held today at 2:00 p.m. CET / 9:00 a.m. EDT
MARSEILLE, France--(BUSINESS WIRE)--#ADC--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “...
|
|
|
20.03.25 - 07:06
|
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Thursday, March 27, 2025 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2024.
Participants during the call will be:
Jonathan Dickinson, Chief Executive Officer
Sonia Quaratino, Executive Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Details for the Virtual Event
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/485278198
Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4I39065986
This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the we...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
